Amgen Inc (NAS:AMGN)
$ 305.84 -0.66 (-0.22%) Market Cap: 164.06 Bil Enterprise Value: 218.38 Bil PE Ratio: 43.69 PB Ratio: 32.64 GF Score: 91/100

Amgen Inc Investor Meeting at ASCO20 Virtual Scientific Program Transcript

May 29, 2020 / 08:00PM GMT
Release Date Price: $229.7 (+2.49%)
Operator

My name is Ian, and I will be your conference facilitator today for Amgen's conference call in conjunction with the ASCO 2020 Virtual Scientific Program. (Operator Instructions)

I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Arvind Sood
Amgen Inc. - VP of IR

Thanks, Ian. Good afternoon, everybody. Thanks for joining us. Would have been great to see you all in person as we normally do at ASCO, but given this year's virtual format, I'm glad that at least we have an opportunity to connect virtually.

So we have presented some important data at this year's ASCO, particularly on AMG 510, or sotorasib, as we now call it, which is our novel small molecule inhibitor of KRAS G12C. Now one portion of the study known as CodeBreaK 100 relates to activity in advanced colorectal cancer patients, and the other is Phase I data in patients with advanced solid tumors other than non-small cell lung cancer and colorectal cancer. We also presented some updated results from a Phase I dose escalation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot